S
Scribe Therapeutics
Biotech & Life Sciences · Alameda, United States · Founded 2017
Focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders MoreLess
Scribe Therapeutics, operating under the website scribetx.com, is a biotechnology startup that specializes in genetic medicine. The company leverages the revolutionary CRISPR technology to engineer advanced solutions for treating genetic diseases. CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing tool that allows scientists to alter DNA sequences and modify gene function. In simpler terms, it's like a molecular scissor that can cut and paste genes, potentially fixing genetic defects or diseases.
Scribe Therapeutics serves a broad range of clients, including healthcare providers, research institutions, and pharmaceutical companies. It operates in the rapidly growing genetic medicine market, which is expected to reach $10.1 billion by 2026, according to a report by Global Market Insights.
The business model of Scribe Therapeutics is based on developing and licensing its proprietary CRISPR-based genetic medicine platform. The company generates revenue by partnering with other companies to develop gene therapies and by licensing its technology to third parties.
Scribe Therapeutics is also developing novel viral and non-viral delivery technologies to enable in vivo genetic medicine, which means treating diseases inside the body by editing genes. The company's technology is designed for exceptional specificity within the genome, which allows for precise therapeutic interventions and allele-specific targeting. An allele is a variant form of a gene, and targeting specific alleles can potentially treat genetic diseases caused by specific gene variants.
In summary, Scribe Therapeutics is a cutting-edge biotech startup that is pioneering the future of genetic medicine by leveraging advanced CRISPR technology.
Keywords: Biotechnology, Genetic Medicine, CRISPR Technology, Healthcare Providers, Research Institutions, Pharmaceutical Companies, Genetic Medicine Market, Gene Therapies, In Vivo Genetic Medicine, Allele-Specific Targeting.
Company overview
Scribe Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Alameda, United States
- Employees
- 87
- Open positions
- None listed
- Dealroom signal
- 62.9
Valuation & funding
Scribe Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jun 2026 | $25M | — | California Institute for Regenerative Medicine | ↗ |
| CONVERTIBLEOther financing | May 2023 | $0 | — | Prevail Therapeutics | ↗ |
| SERIES BOther financing | Mar 2021 | $100M | $400M | Wellington Management · OrbiMed · RA Capital Management · Perceptive Advisors | — |
| SERIES AOther financing | Oct 2020 | $20M | $80M | Biogen | — |
| SPINOUTOther financing | Dec 2018 | — | — | University of California, Berkeley | — |
| SERIES AOther financing | Jan 2018 | Andreessen Horowitz | — |
Growth signals
Scribe Therapeutics website traffic
Latest recorded traffic for Scribe Therapeutics is 18K monthly website visits, up 143.2% over the last three months. Scribe Therapeutics's team declined 18.7% over the past year.
Hiring
Open positions at Scribe Therapeutics
Current openings linked to this company in Dealroom.
Comparisons
Scribe Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Scribe Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Scribe Therapeutics has talent and traffic
team presence
In the news
Latest news about Scribe Therapeutics
Recent press, funding announcements, and product moves mentioning Scribe Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Scribe Therapeutics
An AI-synthesized read of the highest-engagement posts about Scribe Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Scribe Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.